Intervacc is trading 17.13% down at €0.06 after a sharp decline during the September 15, 2026 session, amid broader biotech-sector weakness and fragile risk sentiment.
- No clear company-specific catalyst was identified.
- The only recent announcement was participation in the Swiss Nordic Bio Conference on October 1, which is not a material negative event.
- Biotech ETF XBI is down 2.11%.